Pulmatrix Q2 2026 net loss narrows to $1.0 million; Eos merger expected to close in Q3
Pulmatrix reported a second quarter 2026 net loss of $1.0 million, or $0.29 per share, down from $1.5 million, or $0.42 per share, a year earlier, as general and administrative expenses fell. Cash and cash equivalents were $2.2 million at June 30, 2026, down from $4.1 million at December 31, 2025, and the company said clinical development is on hold while it works to license or monetize its clinical assets. The proposed merger with Eos SENOLYTIX is still expected to close in the third quarter of 2026, subject to customary closing conditions.
Key points
- Net loss for the three months ended June 30, 2026 was $1.0 million ($1,036 thousand), compared with $1.5 million in the same period of 2025
- General and administrative expenses were $1.0 million, down about $0.5 million from $1.5 million a year earlier
- Cash and cash equivalents were $2.2 million at June 30, 2026, versus $4.1 million at December 31, 2025, and the company said this is sufficient to fund operations at least through the anticipated merger closing
- Merger with Eos SENOLYTIX, announced March 26, 2026, is anticipated to close in the third quarter of 2026; Form S-4 was initially filed July 9, 2026 and amended August 3, 2026
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.